HIV theranostics that enables the in vivo imaging of antiretroviral drugs is a powerful tool for the development of antiretrovirals (ARVs) targeting HIV reservoirs, and the development of long-acting ARVs that affect drug adherence and as such reduce viral transmission, prevent new infections, and limit the emergence of viral drug resistance. We tested the possibility to develop HIV theranostics based on the intrinsic CEST contrasts of ARVs. Herein, we measured the CEST effects of first-line ARVs including 3TC (lamivudine) and FTC (emtricitabine) and developed CEST MRI methods for in vivo detection of ARVs in the central nervous system (CNS).
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords